Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;21(1):1-10.
doi: 10.1007/s00198-009-1055-2.

Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

I D Cameron  1 , S Robinovitch, S Birge, P Kannus, K Khan, J Lauritzen, J Howland, S Evans, J Minns, A Laing, P Cripton, S Derler, D Plant, D P Kiel
Affiliations

Hip protectors: recommendations for conducting clinical trials--an international consensus statement (part II)

I D Cameron et al. Osteoporos Int. 2010 Jan.

Abstract

Introduction: While hip protectors are effective in some clinical trials, many, including all in community settings, have been unable to demonstrate effectiveness. This is due partly to differences in the design and analysis. The aim of this report is to develop recommendations for subsequent clinical research.

Methods: In November of 2007, the International Hip Protector Research Group met to address barriers to the clinical effectiveness of hip protectors. This paper represents a consensus statement from the group on recommended methods for conducting future clinical trials of hip protectors.

Results and conclusions: Consensus recommendations include the following: the use of a hip protector that has undergone adequate biomechanical testing, the use of sham hip protectors, the conduct of clinical trials in populations with annual hip fracture incidence of at least 3%, a run-in period with demonstration of adequate adherence, surveillance of falls and adherence, and the inclusion of economic analyses. Larger and more costly clinical trials are required to definitively investigate effectiveness of hip protectors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest S.N. Robinovitch is a paid consultant to Tytex A/S, manufacturer of the Safehip line of wearable hip protectors.

S.J. Birge has served on speakers’ bureaus for Merck, Novartis, Wyeth and as a consultant to Glaxo-Smith Kline and Pfizer.

P. Kannus has received grant funding, lecturing fees, or consulting fees from Aventis, MSD, Novartis, Pfizer, Respecta, and Roche.

J.B. Lauritzen has been a paid consultant to Tytex A/S until 2006.

S.L. Evans is was a consultant to the Ascent Group on hip protector design and testing and is currently a consultant to Dow Corning on impact protection materials and testing.

R.J. Minns received financial assistance from WinHealth (the European distributors of HipSaver hip protectors) for the construction of the test rig in his laboratory.

A.C. Laing has received funding for conference travel from Tytex A/S.

D.P. Kiel has received grants, served on advisory boards, or served on speakers’ bureaus for Eli Lilly, Novartis, Merck, Procter and Gamble, Amgen, GSK, Pfizer, Lifeline, and Hologic.

References

    1. Gullberg B, Johnell O, Kanis JA. Worldwide projections for hip fracture. Osteoporosis Int. 1997;7:407–413. - PubMed
    1. Parker MJ, Gillespie WJ, Gillespie LD. Hip protectors for preventing hip fractures in older people. Cochrane Database of Systematic Reviews. 2005;2005(3) doi: 10.1002/14651858.CD001255.pub3. Art. No.: CD001255. - DOI - PubMed
    1. Sawka AM, Boulos P, Beattie K, et al. Do hip protectors decrease the risk of hip fracture in institutional-and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2005;16:1461–1474. - PubMed
    1. Segui-Gomez M, Keuffel E, Frick KD. Cost and effectiveness of hip protectors among the elderly. Int J Technol Assess Health Care. 2002;18:55–66. - PubMed
    1. Colon-Emeric CS, Datta CK, Matchar DB. An economic analysis of external hip protector use in ambulatory nursing facility residents. Age Ageing. 2003;32:47–52. - PubMed

Publication types